Aurobindo Pharma Limited: Business Overview, Financials & Competitive Analysis
Aurobindo Pharma Limited scores 7/10 on the AskCyborg Cyborg Score (Strong). Diversified global pharma with strong generics presence achieving consistent mid-to-high single-digit growth, backed by strategic expansion into high-margin products and emerging markets. Revenue in 2024 was ₹317.24 billion, an increase of 9.39% compared to the previous year, and Q3 FY26 consolidated revenue rose 8.4% year-on-year to ₹8,646 crores. The.
What is Aurobindo Pharma Limited's industry? Aurobindo Pharma Limited (aurobindo.com) operates in Pharmaceuticals - Generic & Specialty. AskCyborg classifies Aurobindo Pharma Limited under Pharmaceuticals - Generic & Specialty in its company registry.
Aurobindo Pharma is a biopharmaceutical company that develops, manufactures, and commercializes generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables across therapeutic areas including CNS...
Cyborg Score thesis
Diversified global pharma with strong generics presence achieving consistent mid-to-high single-digit growth, backed by strategic...
Read the full analyst-debate transcript →Get the Latest Aurobindo Pharma Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAurobindo Pharma Limited Overview
Pro stress-test →Aurobindo Pharma is a biopharmaceutical company that develops, manufactures, and commercializes generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables across therapeutic areas including CNS, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. The company markets products in over 125 countries with a majority of revenue generated from the United States, making it a critical player in the global generic pharmaceuticals market.
Strategic Profile
Pro stress-test →Aurobindo derives over 70% of its revenues from international operations, primarily from the U.S. The company plans to expand its product portfolio with high-value products in oncology, hormones, biosimilars, and novel drug delivery solutions, while projecting EBITDA margins of 20-21% and over €1 billion revenue from Europe for FY'26.
Competitive Landscape
Pro stress-test →Within the Indian pharmaceutical sector, competitors like Sun Pharma and Dr. Reddy's Laboratories have reported strong results driven by U.S. generics businesses and increasing focus on specialty products. Aurobindo's diversified geographical presence and pipeline development in complex generics and biosimilars position it for continued expansion, offering differentiation through strategic geographic and product diversification.
Industry Context
Aurobindo Pharma Limited operates in Pharmaceuticals - Generic & Specialty.
Key facts
Founded: 1986 · Headquarters: Hyderabad, India · Employees: 40,750 · Revenue: $3.76B · Market cap: $7.1B